Myelodysplastic Syndromes: all 2,165 studies

Page 6 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)CompletedNCT02345850Phase 3Results posted
• Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and ThrombocytopeniaCompletedNCT02335268Phase 2Results posted
• Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)TerminatedNCT02319369Phase 1Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesCompletedNCT02296242Phase 1/2Results posted
• Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic SyndromesCompletedNCT02281084Phase 2Results posted
• Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)CompletedNCT02269280Phase 2Results posted
• Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)CompletedNCT02268383Phase 2Results posted
• Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior TransplantationTerminatedNCT02259348Phase 2Results posted
• Phase I/II Trial to Investigate BI 836858 in Myelodysplastic SyndromesTerminatedNCT02240706Phase 2Results posted
• An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS PatientsCompletedNCT02238925Phase 2Results posted
• Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic SyndromesCompletedNCT02228525Phase 2Results posted
• Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaCompletedNCT02201329Phase 1Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• Darbepoetin Alfa MDS Companion ProtocolCompletedNCT02175277Phase 3Results posted
• Nonmyeloablative Haploidentical Transplant Followed by MLN9708CompletedNCT02169791Phase 2Results posted
• Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) FailureCompletedNCT02159872Phase 2Results posted
• Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.TerminatedNCT02159040Phase 2Results posted
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)TerminatedNCT02158936Phase 3Results posted
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesCompletedNCT02158858Phase 1/2Results posted
• A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)CompletedNCT02145026Phase 4Results posted
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)CompletedNCT02125877Phase 2Results posted
• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative NeoplasmCompletedNCT02121418Not applicableResults posted
• Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT02103478Phase 1/2Results posted
• Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent EngraftmentCompletedNCT02099266Not applicableResults posted
• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02085408Phase 3Results posted
• Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/2Results posted
• Post Transplant Cyclophosphamide (Cytoxan) for GvHD ProphylaxisCompletedNCT02065154Phase 2Results posted
• Adoptive Transfer of Haplo-identical DLI for AML and MDSCompletedNCT02046122Phase 1/2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT02044796Phase 1/2Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell TransplantTerminatedNCT02038153Phase 1/2Results posted
• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02019069Phase 2Results posted
• Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)CompletedNCT02016781Phase 2Results posted
• Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedNCT02014051Phase 1Results posted
• Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)TerminatedNCT02010645Phase 2Results posted
• A Study of Galunisertib in Participants With Myelodysplastic SyndromesCompletedNCT02008318Phase 2/3Results posted
• Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and MyelodysplasiaCompletedNCT02007863Not applicableResults posted
• Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyCompletedNCT02002936Phase 1Results posted
• Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyCompletedNCT02000154Phase 1Results posted
• Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapseCompletedNCT01995578Phase 2Results posted
• Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based TherapyCompletedNCT01980056Phase 1/2Results posted
• Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMMLTerminatedNCT01957644Phase 1Results posted
• A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)CompletedNCT01953692Phase 1Results posted
• Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedNCT01943851Phase 2Results posted
• Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
• Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML PatientsCompletedNCT01929408Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous TherapyTerminatedNCT01902381Phase 2Results posted
• Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaStatus unknownNCT01894477Phase 2Results posted
• Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)CompletedNCT01893372Phase 2Results posted
• Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT01893320Phase 1/2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationCompletedNCT01891968Phase 2Results posted
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCTCompletedNCT01885897Phase 1/2Results posted
• Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT01885689Phase 2Results posted
• A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic SyndromeTerminatedNCT01880437Phase 2Results posted
• Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity AssayCompletedNCT01872819Not applicableResults posted
• Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.CompletedNCT01868477Phase 2Results posted
• Preventing Stem Cell Transplant Complications With a Blood Separator MachineCompletedNCT01866839Phase 1/2Results posted
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenCompletedNCT01858740Phase 2Results posted
• Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT01846624Phase 2Results posted
• Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)CompletedNCT01842646Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CompletedNCT01835587Phase 1/2Results posted
• Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01831232Not applicableResults posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)CompletedNCT01822691Phase 2Results posted
• Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HMCompletedNCT01816230Phase 1/2Results posted
• Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell TransplantCompletedNCT01812252Phase 2Results posted
• Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic SyndromeCompletedNCT01807091Not applicableResults posted
• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01804101Not applicableResults posted
• Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical DonorCompletedNCT01794299Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• GVAX vs. Placebo for MDS/AML After Allo HSCTTerminatedNCT01773395Phase 2Results posted
• Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic AnemiaCompletedNCT01772420Phase 2Results posted
• Unrelated Umbilical Cord Blood (UBC)TransplantationCompletedNCT01768845Not applicableResults posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic SyndromeCompletedNCT01751867Phase 3Results posted
• Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)CompletedNCT01749514Phase 2Results posted
• Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine FailureTerminatedNCT01748240Phase 2Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic MalignanciesTerminatedNCT01745913Phase 2Results posted
• Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01736683Phase 2Results posted
• Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT01729845Phase 1/2Results posted
• Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC TransplantCompletedNCT01720264Phase 2Results posted
• Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 RiskCompletedNCT01720225Phase 2Results posted
• Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01707004Phase 2Results posted
• A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk MyelodysplasiaTerminatedNCT01701375Phase 1Results posted
• Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDSCompletedNCT01700673Phase 2Results posted
• Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedNCT01700335Phase 1Results posted
• A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous PlerixaforCompletedNCT01696461Phase 2Results posted
• E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesCompletedNCT01692197Phase 2Results posted
• Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic SyndromesCompletedNCT01690520Phase 2Results posted
• Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
• Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
• Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological MalignanciesCompletedNCT01682226Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted

← Myelodysplastic Syndromes overview